NBIO .05 - On December 7, 2020, the Company received a letter from the Federal Drug Administration (FDA) releasing the partial hold on the Company’s antibody Pritumumab. The release clears the Company to begin phase 1 clinical trials with its drug substance product.
Based on the approval by the FDA, the Company anticipates clinical trials to begin the first week in January, 2021.
Market Data 
Markets 
AI
